- 现金
- 544 元
- 精华
- 0
- 帖子
- 484
- 注册时间
- 2015-6-1
- 最后登录
- 2016-10-7
|
Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it will host an analyst day in New York on September 24, 2015, with a presentation starting at 11:00 a.m. EDT to discuss ARC-520, its candidate for the treatment of chronic hepatitis B infection. During the event, Arrowhead management and a panel of key opinion leaders will discuss results of the Heparc-2001 Phase 2a study and results of a nonclinical study conducted in 9 chimpanzees chronically infected with hepatitis B virus. |
|